Recruiting

Meloxicam & Acetaminophen

Sponsor:

University of Oklahoma

Code:

NCT07200544

Conditions

Postoperative Pain, Acute

Skin Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Meloxicam 7.5 mg

Meloxicam 15 mg

Acetaminophen 500mg

Study Details

Brief summary:

The goal of this clinical trial is to explore alternative methods of postoperative pain control in Mohs micrographic surgery. The main aims are:

  • To provide more information to the Mohs surgery community regarding postoperative pain control.
  • Reducing pain improves the overall comfort and well-being of patients, leading to a better post-operative experience.
  • To provide patients with an alternative and potentially superior NSAID for pain control (compared to standard-of-care ibuprofen).

Researchers will compare 1) a single of dose Meloxicam 7.5 mg, followed by acetaminophen 500 mg; 2) a single dose of Meloxicam 15 mg, followed by acetaminophen 500 mg; 3) a single dose of acetaminophen 500 mg, followed by alternating ibuprofen 200 mg and acetaminophen 500 mg to see which better moderate pain control and patient satisfaction.

Participants will be asked to complete pain and patient satisfaction surveys.

Conditions

Postoperative Pain, Acute

Skin Cancer

Study ID

NCT07200544

Start date

Oct 15, 2025

Status verified date

Dec, 2025

Completion date

Aug 2, 2026

Anticipated

Primary completion date

Jun 2, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • All adult patients who consents to the study and are undergoing Mohs micrographic surgery at the University of Oklahoma.

Exclusion Criteria:

  • Women who are pregnant, suspected to be pregnant, or planning to become pregnant during the study period will be excluded from participation.
  • Chronic liver disease (chronic hepatitis, acute hepatitis, cirrhosis, NASH, NAFLD, alcoholic liver disease, hemochromatosis, Wilson's disease)
  • Chronic kidney disease stage III or greater,
  • Aspirin-sensitive asthma
  • History of chronic NSAID use
  • Patients vulnerable to drug interactions
  • GI bleeds
  • Peptic ulcers
  • Non-English speakers

Study Design

Enrollment

300 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

active comparator: Standard of Care (Acetaminophen/Ibuprofen)

This randomized control group will take a mandatory one-time dose of 500 mg acetaminophen with alternating 200 mg ibuprofen and 500 mg acetaminophen (standard of care) every 3 hours for pain.

experimental: Meloxicam 7.5 mg

This randomly assigned experimental group will take a mandatory one-time dose of oral Meloxicam 7.5 mg with as-needed acetaminophen 500 mg every 3 hours. Administration of Meloxicam will be upon completion of Mohs closure.

experimental: Meloxicam 15 mg

This randomly assigned experimental group will take a mandatory one-time dose of oral Meloxicam 15 mg with as-needed acetaminophen 500 mg every 3 hours. Administration of Meloxicam will be upon completion of Mohs closure.

Interventions

Meloxicam 7.5 mg

This intervention is the mandatory oral Meloxicam 7.5mg dose after Mohs closure.

Meloxicam 15 mg

This intervention is the mandatory oral Meloxicam 15mg dose after Mohs closure.

Acetaminophen 500mg

This randomized control group will take a mandatory one-time dose of 500 mg acetaminophen with alternating 200 mg ibuprofen and 500 mg acetaminophen (standard of care) every 3 hours for pain.

Primary outcome measure

  • To evaluate the effect of the use of Meloxicam vs SoC on post-operative pain levels in participants undergoing Mohs micrographic surgery. [ Time Frame: From enrollment to suture removal, wound check or flap takedown (7-21 days) ]

Central Contacts and Locations

Central contacts

Chase Pitchford, MD

405-271-6110chase-pitchford@ouhsc.edu

Landon Hendrickson, MD

405-271-6110Landon-Hendrickson@ou.edu

Locations

University of Oklahoma Health Sciences Center

Recruiting

Oklahoma City, Oklahoma, United States, 73104

Contacts

Chase Pitchford

405-271-6110Chase-Pitchford@ouhsc.edu

Lindsey Collins

405-271-6110Lindsey-Collins@ouhsc.edu

Principal Investigator:

Lindsey Collins, MD

More Information

Sponsor

University of Oklahoma

Last update posted

Dec 15, 2025

Last verified

Dec, 2025

Keywords

  • Mohs micrographic surgery
  • Postoperative Pain
  • NSAID
  • Acetaminophen

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Oklahoma on 2025-12-15.